MEDI ASSIST HEALTH SER L

NSE: MEDIASSIST

Healthcare PlansHealthcareSMALL CAP•MCap ₹2.29k Cr

₹305.95₹-0.25 (-0.08%)

Market Closed • NSE

Market cap₹2.29k Cr

Enterprise value₹2.11k Cr

P/E TTM24.15

Forward P/E16.90

P/B2.66

EPS TTM₹12.67

Forward EPS₹18.10

ROCE20.40%

D/E6.38

Dividend yield0.01%

Face value₹5.00

52W high₹575.55

52W low₹291.25

Price chart(1Y)

1Y Return:-17.98% (₹67.05)

H: ₹387L: ₹291.25

1W+1.88%

1M-4.73%

3M-14.38%

6M-15.75%

1Y-45.36%

Today at a glance

Day range

₹303.65₹312.40

52 week range

₹291.25₹575.55

Volume107.5K0.40x 20D avg

Free float50.00%-60.50% volume

MEDI ASSIST HEALTH SER L closed at INR305.95 (-0.08%) on volume 0.4x its 20-day average, trading 46.84% below its 52-week high.

Technical analysis

RSI (14)43.8Neutral (30–70)

MACDBULLISHBullish (Above signal)

ATR (14)₹10.55High

SMA 20₹309.96BEARISH

SMA 50₹327.53BEARISH

SMA 100₹343.88BEARISH

SMA 200₹361.07BEARISH

CPR bottom₹307.60

Pivot₹307.13

CPR top₹306.67

What changed recently?

2026-Q2

Q2 FY2026 Financial Results

PAT moved -7.1% QoQ

2026-09-11

DIVIDEND Announced

Dividend - Rs 2 Per Share

2024-09-06

DIVIDEND Announced

Dividend - Rs 4 Per Share

Shariah audit

Methodology: AAOIFI Shariah Standard No. 21

PASS4/4 criteria

Shariah Compliant

Criteria	Numerator	Denominator	Value	Threshold	Status
Interest-bearing debt ratio	₹54.4 Cr	₹2.29k Cr	2.38%	≤ 33%	PASS
Non-halal income ratio	–	₹904.8 Cr	0.00%	≤ 5%	PASS
Illiquid assets ratio	₹1.32k Cr	₹1.37k Cr	96.02%	≥ 20%	PASS
Receivables ratio	–	₹1.37k Cr	—	≤ 49%	PASS

Valuation & sector context

MetricCompanySector

P/E24.1537.00

Forward P/E16.90—

P/B2.665.00

EV/EBITDA—18.00

PEG—1.00

Earnings yield4.102.70

Growth & profitability

RevenuePAT

FY24PAT margin 10.60%

FY25PAT margin 12.60%

FY26PAT margin 9.70%

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y+81.60%

Revenue CAGR 5Y+7.40%

PAT CAGR 3Y+38.60%

PAT CAGR 5Y+5.60%

Operating margin11.06%

Net margin9.80%

Financial health & cash flow

Net debt–Moderate

Interest coverage4.60xEBIT / interest

CFO / PAT1.37x3Y average

Net debt / EBITDA—Leverage

Operating cash flow₹118.1 Cr

Capital expenditure–

Free cash flow₹62.1 Cr

Financial statements

Complete reported financial history · Values use the company's reporting currency

Hover over the chart for exact reported values. Percentage lines use the right-hand axis.

Fundamental scorecard

Overall78/100

Valuation60/100

Profitability80/100

Financial health95/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Strong Capital Efficiency: ROCE stands at 20.4%

Low Debt Profile: Debt-to-Equity is comfortable at 0.06x

High Cash Flow Conversion: CFO/PAT averaged 1.37x over last 3 years

Risks

Subject to cyclical raw material and macro industry pressures

Bull case

Market Leadership: Established operational scale in Healthcare Plans.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Shareholding pattern

Quarterly ownership historyLatest valid period · December 2024

Ownership distribution

Dec 2024Latest holding

Category trends

Hover over a period for exact holdings

72.66%Institutional holding

22.74%Public holding

2Periods available

0.00%Promoter pledged

88.15KShareholders

Corporate Action

Complete dividend, bonus, split, rights and other action history

Record date	Corporate action	Information	Announcement date	Ex-date
11 Sept 2026	Dividend	₹2.00 / share	—	11 Sept 2026
06 Sept 2024	Dividend	₹4.00 / share	—	06 Sept 2024

Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)60.68%-4.25% latest vs average

Highest delivery77.66%on 22 Sept

Average volume (20D)272.0KTrading-session average

Conviction trendWeakening-4.25% latest reading

Traded volumeDelivery %

Peer comparison

Compare valuation, latest quarterly performance and year-on-year growth

8 companies

Company name	Market cap ₹ Cr	P/E ratio	Dividend yield %	Quarterly sales ₹ Cr	Profit after tax ₹ Cr	Sales growth %	Profit growth %
Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis	₹4.22L	34.90	0.91%	₹15,300.00	₹2,901.00	+10.46%	+26.52%
Divi's Laboratories LimitedDIVISLAB Open analysis	₹2.43L	82.97	0.33%	₹3,080.00	₹902.00	+27.80%	+65.50%
Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis	₹1.73L	72.83	0.83%	₹4,128.00	₹389.00	+41.90%	-21.89%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis	₹1.13L	54.32	0.25%	₹7,044.00	₹610.00	+20.58%	+38.32%
Zydus Lifesciences LimitedZYDUSLIFE Open analysis	₹1.12L	25.03	0.09%	₹8,017.00	₹990.00	+21.95%	-34.91%
LENSKART SOLUTIONS LTDLENSKART Open analysis	₹1.12L	174.73	0.00%	₹2,714.00	₹228.00	+43.29%	+273.77%
Laurus Labs LimitedLAURUSLABS Open analysis	₹1.11L	101.83	0.12%	₹2,026.31	₹367.60	+29.10%	+125.49%
Cipla LimitedCIPLA Open analysis	₹1.07L	31.78	0.98%	₹7,119.00	₹786.00	+2.33%	-39.16%

About MEDI ASSIST HEALTH SER L

Incorporated in June 2000, Medi Assist Healthcare Services Limited is a health-tech and insurance-tech company that manages health benefits for employers, retail members, and public health schemes, primarily serving insurance companies.[1]

IndiaHealthcare

Questions investors ask

Is MEDI ASSIST HEALTH SER L Shariah compliant?

MEDI ASSIST HEALTH SER L is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2.38%) complies with AAOIFI threshold (≤ 33%).

What is MEDI ASSIST HEALTH SER L's current valuation relative to peers?

MEDI ASSIST HEALTH SER L trades at a P/E of 24.1x compared to the sector median of 37x, and a Price-to-Book of 2.7x.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of 0.06x. Interest coverage is 4.6x.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at 7.4% while net profit growth averaged 5.6%.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.